Predicting radiation lung injury after lung cancer treatment
Part of Injuries & trauma, Lungs & breathing clinical trials.
This study looks at ways to predict who will develop radiation pneumonitis (lung inflammation after radiation) and how outcomes vary. It may help doctors better watch and treat lung side effects after lung cancer radiation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of lung cancer based on tissue testing (biopsy or surgery sample)
- You are getting or have received at least 45 Gy of radiation to the chest/lungs
- You are older than 18
- Your health/function is good enough (Karnofsky score over 60, meaning you can do some daily activities)
- You are expected to live at least 6 more months
- You have not had any previous radiation to the chest area
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at cells from the lungs of people who developed lung inflammation after chest radiation for cancer. It aims to understand why some people get this reaction, which may help find better treatments.
This study looks at how radiation therapy for breast cancer may affect your lungs over time. Researchers will measure lung function and see if problems develop, so they can better understand and protect patients.
This study looks at whether certain biological markers can predict lung injury in people receiving both immunotherapy and radiation for lung cancer. The goal is to identify who might be at higher risk, so treatment can be tailored to reduce harm.
This study looks for signs in the blood that can tell if a lung cancer patient is developing a side effect called pneumonitis (lung inflammation) from checkpoint inhibitor treatment. It may help doctors catch and treat this side effect early.
This study looks for early “predictive markers” to tell who is most likely to develop lung inflammation after standard treatment for non-small cell lung cancer. It may help clinicians spot problems sooner and tailor care, using additional monitoring during treatment.
This study is looking for biomarkers (genetic clues) to predict how patients will react to radiation after breast-conserving surgery. It aims to create a model that can personalize treatment to reduce side effects.
Hear when a new Radiation Pneumonitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.